EMOSIS is a young company founded in 2015 that develops and markets innovative blood tests to improve the care of patients with cardiovascular diseases in a more reliable and faster manner. These diseases, such as stroke, myocardial infarction, or pulmonary embolism, are the leading causes of death in the world. They have in common the development of thrombosis, for which blood tests enabling their diagnostics are currently limited. To overcome this problem, EMOSIS has placed blood cells at the heart of its diagnostics innovation by developing a new class of test. In 2018, the first Emo-test named HIT Confirm is marketed, in Europe for clinical use (CE Mark) and outside Europe for research use (RUO), with the aim of helping to establish the diagnosis of Heparin-Induced Thrombocytopenia (HIT). Since its inception, EMOSIS has been open to the world through an international network of distributors. The company’s premises are based in Illkirch (France) and EMOSIS LTD, our Israeli subsidiary created in 2017, is located in Tel-Aviv. Focused on the future and on the human being, EMOSIS is involved in a management innovation founded on 4 values: ethic, pedagogy, quality, and empowerment.